Search results
Results from the WOW.Com Content Network
Serious side effects may include rhabdomyolysis, liver problems, and diabetes. [5] Use during pregnancy may harm the fetus. [5] Like all statins, pravastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver that plays a role in producing cholesterol. [5] Pravastatin was patented in 1980 and approved for medical use in 1989. [6]
The most common side effects are abdominal distension (bloating), abdominal pain (stomach ache), constipation, diarrhea, dry mouth, dyspepsia (heartburn), eructation (belching), flatulence (gas), nausea (feeling sick), abdominal discomfort, vomiting and raised blood levels of liver enzymes.
The most important adverse side effects are muscle problems, an increased risk of diabetes mellitus, and increased liver enzymes in the blood due to liver damage. [ 5 ] [ 66 ] Over 5 years of treatment statins result in 75 cases of diabetes, 7.5 cases of bleeding stroke , and 5 cases of muscle damage per 10,000 people treated. [ 35 ]
“Cardiovascular disease remains a leading cause of disability and death. In addition to statin treatment, people at high cardiovascular risk need further effective and cost-effective treatments ...
For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...
The case arose in a dispute between Mayo Collaborative Services and Prometheus Laboratories concerning a diagnostic test. Mayo Collaborative Services is a for-profit [6] diagnostic testing lab offering diagnostic services that operates as a subsidiary of Mayo Foundation for Medical Education and Research, [7] which is a nonprofit corporation [8] affiliated with the Mayo Clinic.
Doctors describe a clearer, more consistent pattern of Covid symptoms than they saw in the past. The illness often starts with sore throat and congestion.
The Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 trial, also known as PROVE-IT TIMI 22, was a randomized, double-blind, clinical trial that recruited 4,162 people admitted within 10 days of an acute coronary event and randomised them to the lipid-lowering drugs pravastatin (40 mg) or atorvastatin (80 mg) and a 10-day course of the ...